This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Greatbatch, Inc. Reports 2012 Second Quarter Results

Cash flows from operations for the second quarter of 2012 were approximately $24 million compared to $13 million in the 2011 period. During the second quarter of 2012, the Company repaid $8 million of long-term debt. Going forward, cash flows from operations will be used to fund our consolidation and RD&E initiatives, as well as to pay down long-term debt.

 
Product Line Sales
The following table summarizes the Company’s sales by major product lines (dollars in thousands):
 
  Three Months Ended
June 29,   July 1,   %   March 30,   %

Product Line

  2012   2011 Change   2012 Change
Implantable Medical
CRM/Neuromodulation $ 80,025 $ 77,724 3 % $ 75,135 7 %
Vascular Access 12,481 10,769 16 % 11,636 7 %
Orthopaedic   32,860   37,922 -13 %   31,046 6 %
Total Implantable Medical 125,366 126,415 -1 % 117,817 6 %
Electrochem

Portable Medical

20,407

2,012

NA

18,720

9

%

Energy/Environmental 16,879 16,016 5 % 18,370 -8 %
Other   3,896   2,081 87 %   4,196 -7 %
Total Electrochem   41,182   20,109 105 %   41,286 0 %
Total Sales $ 166,548 $ 146,524 14 % $ 159,103 5 %
 

Implantable Medical

CRM and Neuromodulation sales for the second quarter of 2012 increased 3% compared to the prior year to a record $80.0 million. CRM and Neuromodulation revenue for the second quarter of 2012 and 2011 both included the benefit of customer product launches. The Company continues to see an increased pace of product development opportunities from its CRM customers. Management believes that this, combined with our increased focus on sales and marketing, will allow the Company to grow this product line faster than the underlying market.

5 of 10

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs